Search

Manal A Morsy

from Cleveland, OH
Age ~66
Get Report
Also known as:
Manal Dr Morsy, Manal Anwar Morsy, Manal A Morsi, Manal A Orsy, Ma Morsy, Morsy Ma, Loan R
Related to:
Min Wu Yeh, 86Palmira Duarte, 49Joseph Lopes, 44Luis Lopes, 59Darlene Duarte, 64Cecil Lopes
Connected to:
Hazem Morsy, 37Inas Morsy, 35Marwa Morsy, 33Mona A Morsy, 50Andy L Mort, 39Billy W Mort, 55Caroline F Mort, 35Catherine L Mort, 63Debra Mort, 75Eric Mort, 55

Manal Morsy Phones & Addresses

  • Cleveland, OH
  • 189 Canterbury Ct, Blue Bell, PA 19422 (610) 239-7025 (610) 239-9111
  • Florham Park, NJ
  • New York, NY
  • 7777 Greenbriar St, Houston, TX 77030 (713) 795-5060 (713) 795-5062
  • Morristown, NJ
  • Norfolk, VA
  • 189 Canterbury Ln, Blue Bell, PA 19422 (610) 239-7025

Work

Company: Athersys 2016 to 2016 Position: Senior vice president, head of global regulatory affairs

Education

School / High School: The Wharton School 2003 to 2005

Skills

Drug Development • Biotechnology • Clinical Development • Regulatory Affairs • Pharmaceutical Industry • Oncology • Regulatory Requirements • Clinical Trials • Vaccines • Infectious Diseases • Life Sciences • Pharmaceutics • Fda • Regulatory Submissions • Biologics • Neurology • Cell Biology • Clinical Research • Hematology • Therapeutic Areas • Biopharmaceuticals • Pharmacovigilance • Technology Transfer • Immunology • Rare Diseases • Lifesciences • Orphan Drugs • Ema • Pulmonary Diseases • Metabolic Syndrome • Glp • Ind • Global Regulatory Affairs • Stem Cells • Cell Therapy • U.s. Food and Drug Administration • Metabolic Disorders

Languages

English • Arabic

Industries

Biotechnology

Resumes

Resumes

Manal Morsy Photo 1

Manal Morsy

View page
Location:
189 Canterbury Ln, Blue Bell, PA 19422
Industry:
Biotechnology
Work:
Athersys 2016 - 2016
Senior Vice President, Head of Global Regulatory Affairs
Ptc Therapeutics, Inc. 2007 - 2012
Vice President, Head of Global Regulatory Affairs
Johnson & Johnson 2004 - 2007
Senior Director, Global Regulatory Affairs Anti-Infectives
Merck 1995 - 2004
Director, Worldwide Regulatory Affairs Vaccines and Biologics
Baylor College of Medicine 1991 - 1995
Assistant Professor, Human Genetics Department
Education:
The Wharton School 2003 - 2005
Drexel University 2000 - 2002
Master of Business Administration, Masters, Management Eastern Virginia Medical School 1988 - 1991
Doctorates, Doctor of Philosophy, Molecular Biology Alexandria University - Faculty of Medicine 1977 - 1984
Doctor of Medicine, Doctorates, Medicine
Skills:
Drug Development
Biotechnology
Clinical Development
Regulatory Affairs
Pharmaceutical Industry
Oncology
Regulatory Requirements
Clinical Trials
Vaccines
Infectious Diseases
Life Sciences
Pharmaceutics
Fda
Regulatory Submissions
Biologics
Neurology
Cell Biology
Clinical Research
Hematology
Therapeutic Areas
Biopharmaceuticals
Pharmacovigilance
Technology Transfer
Immunology
Rare Diseases
Lifesciences
Orphan Drugs
Ema
Pulmonary Diseases
Metabolic Syndrome
Glp
Ind
Global Regulatory Affairs
Stem Cells
Cell Therapy
U.s. Food and Drug Administration
Metabolic Disorders
Languages:
English
Arabic

Business Records

Name / Title
Company / Classification
Phones & Addresses
Manal Morsy
Vice President Regulatory Affairs
PTC Therapeutics Inc
Research & Development in Biotechnology
100 Corporate Ct, South Plainfield, NJ 07080
(908) 222-7000, (908) 222-7231, (908) 222-7000

Publications

Us Patents

Adenoviral Based Promoter Assay

View page
US Patent:
6395473, May 28, 2002
Filed:
Mar 7, 2001
Appl. No.:
09/743570
Inventors:
Karen Richards - Windmoor PA
Thomas H. Rushmore - Hatfield PA
Manal A. Morsy - Blue Bell PA
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C12Q 168
US Classification:
435 5, 435 6, 435 29, 4353201, 435455, 435456, 435325, 435366, 435370, 435371, 435 914, 435 9141, 435 9142
Abstract:
Adenoviral vectors are used to transfer a promoter/reporter gene construct to mammalian cell cultures. The promoter/reporter gene construct is used to determine if a candidate inducing agent has promoter-inducing activity; or can be used to determine if a candidate promoter has activity in the presence of a known inducer.

Gene Therapy For Obesity

View page
US Patent:
6630346, Oct 7, 2003
Filed:
Apr 1, 1999
Appl. No.:
09/202684
Inventors:
Manal Morsy - Blue Bell PA
MingCheng Gu - Maple Glen PA
Jing Zhang Zhao - Chalfont PA
C. Thomas Caskey - Houston TX
Stephan Kochanek - Ulm, DE
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C12N 500
US Classification:
435325, 435 691, 4353201, 435455, 536 231, 536 235, 514 44
Abstract:
Gene therapy can treat obesity in mammals. An obesity regulating gene is delivered to a mammal. Preferably, the gene encodes leptin or a leptin receptor. The protein which is delivered and expressed in vivo is more effective than protein which is injected into the animal.

Gene Therapy For Obesity

View page
US Patent:
20030215423, Nov 20, 2003
Filed:
Apr 21, 2003
Appl. No.:
10/419549
Inventors:
Manal Morsy - Blue Bell PA, US
Ming Gu - Lansdale PA, US
Jing Zhoa - Lansdale PA, US
C. Caskey - Houston TX, US
Stephan Kochanek - Cologne, DE
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A01K067/00
A61K048/00
C12N015/861
US Classification:
424/093200, 800/008000, 435/456000, 435/457000
Abstract:
Gene therapy can treat obesity in mammals. An obesity regulating gene is delivered to a mammal. Preferably, the gene encodes leptin or a leptin receptor. The protein which is delivered and expressed in vivo is more effective than protein which is injected into the animal.

Methods For Propagating Adenovirus And Virus Produced Thereby

View page
US Patent:
20040106194, Jun 3, 2004
Filed:
Aug 21, 2003
Appl. No.:
10/645794
Inventors:
Andrew Bett - Lansdale PA, US
Michael Chastain - Erdenheim PA, US
Volker Sandig - Berlin, DE
Emilio Emini - Wayne PA, US
John Shiver - Chalfont PA, US
Danilo Casimiro - Harleysville PA, US
David Kaslow - Rancho Santa Fe CA, US
Manal Morsy - Blue Bell PA, US
International Classification:
C12Q001/68
C12N007/00
C12N007/01
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74
US Classification:
435/320100, 435/235100, 435/006000
Abstract:
Various methods for propagating and rescuing multiple serotypes of replication-defective adenovirus in a single adenoviral E1-complementing cell line are disclosed. Typically, replication-defective adenovirus vectors propagate only in cell lines which express E1 proteins of the same serotype or subgroup as the vector. The disclosed methods offer the ability to propagate vectors derived from multiple adenoviral serotypes in a single production cell line which expresses E1 proteins from a single serotype. Propagation in this manner is accomplished by providing all or a portion of an E4 region in cis within the genome of the replication-defective adenovirus. The added E4 region or portion thereof is cloned from a virus of the same or highly similar serotype as that of the E1 gene product(s) of the complementing cell line. Interaction between the expressed E1 of the cell line and the heterologous E4 of the replication-defective adenoviral vectors enables their propagation and rescue. The invention bypasses a need in the art to customize specific cell lines to the serotype or subgroup of the adenoviral vector being propagated and enables one to easily and rapidly develop alternative adenoviral serotypes as gene delivery vectors for use as vaccines or as a critical component in gene therapy.

Adenovirus Serotype 24 Vectors, Nucleic Acids And Virus Produced Thereby

View page
US Patent:
20040185555, Sep 23, 2004
Filed:
Aug 21, 2003
Appl. No.:
10/645883
Inventors:
Emilio Emini - Wayne PA, US
John Shiver - Chalfont PA, US
Andrew Bett - Lansdale PA, US
Danilo Casimiro - Harleysville PA, US
Michael Chastain - Erdenheim PA, US
David Kaslow - Rancho Santa Fe CA, US
Manal Morsy - Blue Bell PA, US
International Classification:
C12Q001/70
C07H021/04
A01N063/00
A61K048/00
C12N015/09
C12N007/01
C12N015/63
C12N007/00
C12N015/70
C12N015/74
C12N015/00
US Classification:
435/320100, 435/235100, 424/093200, 424/093600, 536/023720
Abstract:
Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g, fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 24, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for the delivery and expression of exogenous genes are provided.

Gene Therapy For Leptin Deficiency

View page
US Patent:
6001816, Dec 14, 1999
Filed:
Jun 19, 1997
Appl. No.:
8/878738
Inventors:
Manal A. Morsy - Blue Bell PA
Ming Cheng Gu - Lansdale PA
Jing Zhoa - Lansdale PA
C. Thomas Caskey - Houston TX
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A01N 4304
US Classification:
514 44
Abstract:
Gene therapy can treat obesity in mammals. An adenoviral vector encoding a leptin gene is delivered intravenously to a mammal with a deficiency in functional leptin to decrease weight, decrease serum insulin levels or decrease serum glucose levels.
Control profile
Manal A Morsy from Cleveland, OH, age ~66 Get Report